Management of Heparin in AMI Patients on Oral Coumadin

Rationale for Heparin Administration in AMI Patients on Coumadin

The European Society of Cardiology recommends heparin as a standard anticoagulant therapy during primary PCI for AMI, even in patients already on oral anticoagulants, due to the strong belief that anticoagulation is required during the procedure 1, 2
For patients with AMI requiring immediate cardioversion or intervention due to hemodynamic instability, the American College of Cardiology recommends heparin administration concurrently by an initial intravenous bolus followed by continuous infusion, regardless of prior anticoagulation status 3, 4
The primary goal of heparin therapy in AMI is to prevent early thrombotic complications during and immediately after intervention, which warfarin alone may not adequately address due to its delayed onset of action 5

The European Society of Cardiology recommends administering intravenous heparin bolus at a reduced dose of 60-70 U/kg if the patient is already anticoagulated with warfarin 2, 6
The American College of Cardiology recommends performing the procedure under activated clotting time (ACT) guidance, adjusting heparin to maintain an ACT of 250-350 seconds (or 200-250 seconds if GPIIb/IIIa inhibitors are used) 1, 2
The European Society of Cardiology recommends checking INR prior to heparin administration if possible, and considering further dose reduction if INR is already in therapeutic range (2.0-3.0) 3

The American College of Cardiology recommends more frequent monitoring of aPTT (every 4-6 hours initially) when administering heparin to patients already on warfarin 5
The European Society of Cardiology recommends targeting a lower aPTT range (1.5 times control rather than 1.5-2.5 times) in patients with therapeutic INR values 5
The American Heart Association recommends monitoring closely for signs of bleeding, particularly at vascular access sites during PCI 2, 7

The American College of Cardiology recommends careful assessment of the risk-benefit ratio when administering heparin to patients already on warfarin, due to increased risk of bleeding 3
The European Society of Cardiology recommends considering omitting the heparin bolus and starting with a lower infusion rate for patients with very high INR values (>3.5) 5

The American College of Cardiology recommends checking the patient's baseline INR before administering heparin to avoid excessive anticoagulation and increased bleeding risk 3, 5
The American Heart Association recommends avoiding standard heparin doses in patients already anticoagulated with warfarin, as it significantly increases bleeding complications 7
The American College of Cardiology recommends not discontinuing warfarin completely during AMI management without a proper transition plan, as it can increase thrombotic risk, especially in patients with mechanical heart valves or atrial fibrillation 3, 8